June 13, 2017 / 1:31 PM / a month ago

BRIEF-Pulmatrix to pay Respivert up-front, non-refundable license fee of $1 mln

1 Min Read

June 13 (Reuters) - Pulmatrix Inc-

* Pulmatrix - will pay Respivert up-front, non-refundable license fee of $1 million in partial consideration for rights granted by respivert to company - sec filing

* Pulmatrix - following commencement of commercial sales of licensed products, co will pay respivert designated amounts when certain milestone events occur

* Pulmatrix Inc - development milestones and commercial milestones range from $1 million to $80 million

* Pulmatrix Inc - co required to pay respivert royalties on all sales of licensed products, with such royalties ranging from 6% - 10% of sales Source text: (bit.ly/2swuyjg) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below